Medexus Pharmaceuticals Inc.
MEDXF
$2.00
$0.084.06%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -5.94% | -9.78% | -4.65% | 18.96% | -13.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.94% | -9.78% | -4.65% | 18.96% | -13.27% |
| Cost of Revenue | -19.32% | -23.54% | -11.58% | 17.73% | -15.79% |
| Gross Profit | 3.18% | -0.35% | 0.66% | 19.94% | -11.46% |
| SG&A Expenses | 23.00% | 17.56% | 17.43% | 2.61% | -18.66% |
| Depreciation & Amortization | 54.06% | 72.06% | 68.12% | 21.27% | 7.72% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.99% | 3.54% | 8.24% | 10.86% | -17.07% |
| Operating Income | -59.68% | -80.37% | -110.27% | 141.14% | 15.36% |
| Income Before Tax | 43.72% | -67.63% | -176.67% | 210.69% | 40.29% |
| Income Tax Expenses | 98.26% | 273.68% | -190.35% | 156.32% | -675.83% |
| Earnings from Continuing Operations | -386.36% | -73.63% | -172.57% | 237.27% | 110.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -386.36% | -73.63% | -172.57% | 237.27% | 110.06% |
| EBIT | -59.68% | -80.37% | -110.27% | 141.14% | 15.36% |
| EBITDA | -28.10% | -42.93% | -49.01% | 83.59% | 13.14% |
| EPS Basic | -317.78% | -80.00% | -159.94% | 234.39% | 108.41% |
| Normalized Basic EPS | -102.09% | -99.13% | -96.72% | 208.78% | 260.74% |
| EPS Diluted | -332.56% | -80.00% | -159.94% | 234.39% | 108.04% |
| Normalized Diluted EPS | -102.16% | -99.13% | -96.72% | 208.78% | 255.37% |
| Average Basic Shares Outstanding | 31.53% | 31.89% | 21.08% | 2.04% | 20.14% |
| Average Diluted Shares Outstanding | 27.12% | 31.89% | 21.08% | 2.04% | 24.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |